Screening, monitoring, and treatment of albuminuria: Public health perspectives
Screening, monitoring, and treatment of albuminuria: Public health perspectives
复制标题
DOI：
10.1681/asn.2006010097
复制
发表时间：
2006-08-01
影响因子：
13.6
通讯作者：
Curhan, Gary C.
中科院分区：
文献类型：
--
作者：
de Jong, Paul E.;Curhan, Gary C.
微量白蛋白尿是糖尿病和非糖尿病患者进行性心血管和肾脏疾病的早期征兆。尽管有令人信服的数据，但目前只有少数糖尿病患者和很少的非糖尿病患者以系统的方式进行白蛋白尿筛查。糖尿病患者符合系统性白蛋白尿筛查的所有标准，而非糖尿病患者几乎符合微量白蛋白尿筛查的大多数标准。由于越来越多的证据表明，在没有糖尿病的个体中治疗微量白蛋白尿可以提供预防心血管疾病的成本效益，肾脏病学家和其他医疗保健提供者应该更加关注微量白蛋白尿个体的早期发现和后续治疗。
Microalbuminuria is an early sign of progressive cardiovascular and renal disease in individuals with and without diabetes. Despite compelling data, at present only a minority of patients with diabetes and rarely individuals without diabetes are screened for albuminuria in a systematic way. All of the criteria to implement systematic albuminuria screening are fulfilled in diabetes, and most are nearly fulfilled for microalbuminuria screening in individuals without diabetes. Because of the growing evidence that treatment of microalbuminuria in individuals without diabetes may offer A cost-effective benefit to prevent cardiovascular disease, nephrologists and other health care providers should pay more attention to the early detection and subsequent treatment of individuals with microalbuminuria.